Strengthened Management and Board
Appointment of Jason Tardio as President and COO and Simona Skerjanec to the Board, enhancing the team's expertise in drug commercialization and development.
Immunic
· IMUX
November 7th, 2024
Summary
- Earnings Call Date:
- 2024-11-07
- Change Since:
- +24.66%
- Next Earnings Date:
- 2026-08-06
Earnings Call Sentiment
PositiveThe earnings call presented significant positive developments, including strengthened leadership, progress in key clinical trials, and potential market impact of vidofludimus calcium. However, challenges such as increased R&D expenses and net losses were also noted. The sentiment leans slightly positive due to the promising clinical trial results and potential market opportunities.
Company Guidance
During the Q3 2024 earnings call for Immunic, the company provided several key metrics and guidance concerning its financial status and clinical development programs. Immunic ended the quarter with $59.1 million in cash, which is expected to fund operations into Q3 2025. R&D expenses were reported at $21.4 million for the quarter, reflecting an increase from the previous year due to costs associated with clinical trials, offset by savings from deprioritized programs. The net loss for the quarter was approximately $24.4 million or $0.24 per share. Significant clinical milestones were also discussed, including the anticipated top-line data from the Phase II CALLIPER trial in progressive MS expected in April 2025, and the continuation of the Phase III ENSURE trials in relapsing MS, with the first trial completion expected by Q2 2026. The company also highlighted ongoing interest from pharmaceutical companies for potential partnerships, driven by the innovative profile and market potential of their lead asset, vidofludimus calcium.
Positive Phase III ENSURE Program Interim Analysis
The interim analysis of the Phase III ENSURE program for vidofludimus calcium in relapsing MS showed it is not futile, allowing trials to continue as planned.
Phase II CALLIPER Trial Progress
Ongoing Phase II CALLIPER trial of vidofludimus calcium in progressive MS, with top-line data expected in April 2025.
New Clinical Trial Initiation
Enrollment of the first patient in a Phase II clinical trial of vidofludimus calcium in post-COVID syndrome.
Financial Position
$59.1 million in cash expected to fund operations into the third quarter of 2025.
Potential Market Impact
Vidofludimus calcium is projected to reach peak sales of USD 2 billion to USD 6 billion, transforming the oral disease-modifying therapy market for MS.
Operator
Good morning, and welcome to Immunic’s Third Quarter 2024 Earnings Call. My name is Jessica Breu, Vice President, Investor Relations and Communications at Immunic. I will also be the moderator today. Speaking on the call are Dr. Daniel Vitt, our Chief Executive Officer, Glenn Whaley, our Chief Financial Officer; as well as Jason Tardio, our President and Chief Operating Officer. Please note that all participants will be in listen-only mode, and this event is being recorded. After today’s presentation, there will be an opportunity to ask questions. [Operator Instructions] Before we begin, I would like to remind you that this presentation may contain forward-looking statements.
Such statements can be identified by words such as may, will, expect, anticipate, estimate, or words with a similar meaning. And, such statements involve a number of risks and uncertainties that could cause in Immunic’s actual results to differ materially from those discussed here. Please note that these forward-looking statements reflect Immunic’s opinions only as of the date of this presentation, and it undertakes no obligation to revise or publicly release the result of any revision to these forward-looking statements in light of new information or future events. Please refer to Immunic’s SEC filings for a more detailed description of the risk factors that may affect Immunic’s results and these forward-looking statements. I would now like to turn the call over to our CEO, Dr. Daniel Vitt, to begin the presentation. Daniel?
Daniel Vitt
Thank you, Jessica. I would also like to welcome everybody to today’s Q3 2024...
Subscribe to unlock transcripts
Get The Fly Pro 7 days for free